Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 13/20 | 0.67 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566562 | 0.94 | QPCT (0.62) | QPCTQPCTLNPC1POLB | |
| SCHEMBL77446 | 0.82 | QPCT (0.62) | QPCTQPCTLNPC1POLB | |
| SCHEMBL77921 | 0.82 | QPCT (0.62) | QPCTQPCTLNPC1POLB | |
| SCHEMBL76307 | 0.80 | QPCT (1.00) | QPCTQPCTLMAPTALDH1A1PKM | |
| SCHEMBL77510 | 0.78 | QPCT (0.61) | QPCTNPC1POLBMAPTALDH1A1 | |
| SCHEMBL14156238 | 0.77 | QPCT (0.93) | QPCTQPCTL | |
| SCHEMBL14855986 | 0.76 | QPCT (0.65) | QPCTQPCTLMAPTALDH1A1PKM | |
| SCHEMBL76673 | 0.76 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL76693 | 0.75 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL29410444 | 0.75 | QPCT (1.00) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117540-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008104580-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-09-04 | — | — | WO | disclosed |